Preoperative Chemotherapy, NSABP Protocols B-18 and B-27: an ...

More documents

Recommendations

Info

Tissue for Biomarkers R a n d o m i z e <strong>NSABP</strong> B-40 Her2 Neg ≥2cm T x 4 TX x 4 TG x 4 AC x 4 AC x 4 AC x 4 ± Bevacizumab x 6 Tissue for Biomarkers Endpoints: pCR; 2 0 endpoint: pCR ∆ (29→38%) DFS N=1200 Started: 11-07 S u r g e r y ± B evacIzu m ab
O p e r a b l e B C R AC X 4 AC X 4 AC X 4 <strong>NSABP</strong> B-41 Her2 Pos N=522; pCR ∆ 22% (42→64%) Paclitaxel/wk + Trastuzumab Paclitaxel/wk + Lapatinib Paclitaxel/wk + Lapatinib + Trastuzumab S u r g e r y T m a b
Page 1: Preoperative Chemotherapy, NSABP Pr
Page 5 and 6: B-18 Duration: 88-93 ACCRUAL: 1,523
Page 7 and 8: NSABP B-18 OPENED: Oct. 1988 CLOSED
Page 9 and 10: Tumor Response
Page 11 and 12: 100% 80% 60% 40% 20% 0% Tumor Respo
Page 13 and 14: 100% 80% 60% 40% 20% 0% 42 Nodal Re
Page 15 and 16: Outcome
Page 17 and 18: 100 90 80 70 60 50 40 30 DFS N Ev H
Page 19 and 20: 100 90 80 70 60 50 40 30 Survival N
Page 21 and 22: 100 90 80 70 60 50 40 30
Page 23 and 24: pCR and Outcome
Page 25 and 26: 100 90 80 70 60 50 40 30 N Ev HR No
Page 27 and 28: RESPONDERS AC chemotherapy NON RESP
Page 29 and 30: NSABP B-27 OPENED: Dec. 1995 CLOSED
Page 31 and 32: Tumor Response
Page 33 and 34: 40% 20% 0% Path Complete Response 1
Page 35 and 36: 40% 20% 0% pCR: AC→T 26 26 28 29
Page 37 and 38: % Node + 70 60 50 40 30 20 10 0 pCR
Page 39 and 40: 100 90 80 70 60 50 40 DFS N Ev RR P
Page 41 and 42: 15 10 5 0 Local or IBTR AC AC→T p
Page 43 and 44: pCR and Outcome
Page 45 and 46: 100 90 80 70 60 50 40 pCR v no pCR
Page 47: Txt Resp Txt Non-R N=24 Txt 100mg/m

Preoperative Chemotherapy, NSABP Protocols B-18 and B-27: an ...

Create successful ePaper yourself

Delete template?

Save as template?